Also known as: Sorafenib Tosylate; Nexavar
Sorafenib is an oral multikinase inhibitor with both antiproliferative and antiangiogenic properties used as an active pharmaceutical ingredient. Mediocon Inc supplies high-purity Sorafenib API conforming to BP / EP / USP specifications from our GMP-certified facility in Aurangabad, Maharashtra, India.
Sorafenib inhibits multiple kinases including RAF kinases, VEGFR, and PDGFR, blocking tumor cell proliferation and angiogenesis. It is indicated for unresectable hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma.
Key Features
Applications
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Assay | NLT 98.0% |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Residue on Ignition | NMT 0.1% |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Packing | 25 kg HDPE drums / as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Sorafenib (CAS 475207-59-1) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Sorafenib is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance